Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Browse by Current Cardiff authors

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Number of items: 82.

Uusi-Kerttula, Hanni, Davies, James A, Thompson, Jill, Wongthida, Phonphimon, Evgin, Laura, Shim, Kevin G., Bradshaw, Angela, Baker, Alexander T, Rizkallah, Pierre J, Jones, Rachel, Hanna, Louise, Hudson, Emma, Vile, Richard, Chester, John D and Parker, Alan L 2018. Ad5NULL-A20 - a tropism-modified, αvβ6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer therapies. Clinical Cancer Research 24 (17) , pp. 4215-4224. 10.1158/1078-0432.CCR-18-1089
file

Hulin-Curtis, Sarah, Davies, James A., Jones, Rachel, Hudson, Emma, Hanna, Louise, Chester, John D. and Parker, Alan L. 2018. Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus. Oncotarget 9 (41) , pp. 26328-26341. 10.18632/oncotarget.25242
file

Crabb, Simon J, Martin, Karen, Abab, Julia, Ratcliffe, Ian, Thornton, Roger, Lineton, Ben, Ellis, Mary, Moody, Ronald, Stanton, Louise, Galanopolou, Angeliki, Maishman, Tom, Geldart, Thomas, Bayne, Mike, Davies, Joe, Lamb, Carolynn, Popat, Sanjay, Joffe, Johnathan K, Nutting, Chris, Chester, John, Hartley, Andrew, Thomas, Gareth, Ottensmeier, Christian, Huddart, Robert and King, Emma 2017. COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss. European Journal of Cancer 87 , pp. 75-83. 10.1016/j.ejca.2017.09.033
file

Collins, Jemima T., Noble, Simon, Chester, John, Davies, Helen E., Evans, William D., Farewell, Daniel, Lester, Jason F., Parry, Diane, Pettit, Rebecca and Byrne, Anthony 2017. The value of physical performance measurements alongside assessment of sarcopenia in predicting receipt and completion of planned treatment in non-small cell lung cancer: an observational exploratory study. Supportive Care in Cancer 10.1007/s00520-017-3821-6

Lopes-Bastos, Bruno, Jin, Liang, Ruge, Fiona, Owen, Sioned, Sanders, Andrew J., Cogle, Christopher, Chester, John D., Jiang, Wen Guo and Cai, Jun 2017. Association of breast carcinoma growth with a non-canonical axis of IFNγ/IDO1/TSP1. Oncotarget 10.18632/oncotarget.18781
file

Dabkowski, Adam, Paisey, S. J., Spezi, Emiliano, Chester, John and Marshall, C. 2017. Optimization of Zirconium-89 production in IBA cyclone 18/9 cyclotron with COSTIS solid target system. Presented at: WTTC16: Proceedings of the 16th International Workshop on Targetry and Target Chemistry, Santa Fe, NM, USA, 29 August–1 September 2016. Published in: Engle, Jonathan W., Barnhart, Todd E., Nortier, Francois M., O’Neil, James P., Birnbaum, Eva R. and Gangon, Katherine M. eds. AIP Conference Proceedings. Melville, NY: AIP, 020005. 10.1063/1.4983536

Chester, John D., Bond, Jodie R. and Batt, Elisabeth A. 2017. The Wales Cancer Research Centre: improving cancer care together. ecancermedicalscience 11 , ed65. 10.3332/ecancer.2017.ed65
file

Powles, Thomas, Huddart, Robert, Elliott, Tony, Sarker, Shah-Jalal, Jones, Robert, Hussain, Syed A., Crabb, Simon J., Ackerman, Charlotte, Jagdev, Satinder, Chester, John, Hilman, Serena, Beresford, Mark, Macdonald, A Graham, Sundar, Santhanam, Frew, John A., Stockdale, Andrew, Hughes, Simon, Berney, Daniel and Chowdhury, Simon 2017. Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2–positive metastatic bladder cancer. Journal of Clinical Oncology 35 (1) , pp. 48-55. 10.1200/JCO.2015.66.3468
file

Hulin-Curtis, Sarah, Uusi-Kerttula, Hanni, Jones, R., Hanna, L., Chester, John D. and Parker, Alan L. 2016. Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy. Cancer Gene Therapy 23 (7) , pp. 229-234. 10.1038/cgt.2016.22
file

Uusi-Kerttula, Hanni, Davies, James, Curtis, Sarah, Chester, John and Parker, Alan 2016. Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies. Oncotarget 7 (19) , pp. 27926-27937. 10.18632/oncotarget.8545
file

Jones, Robert J., Crabb, S. J., Chester, John D., Elliott, T., Huddart, R. A., Birtie, A. J., Evans, L., Lester, Jason Francis, Huang, Chao, Casbard, Angela, Madden, Tracie-Ann and Griffiths, Gareth 2016. TOUCAN: A randomised phase II trial of carboplatin and gemcitabine plus /- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin [Abstract]. American Journal of Clinical Oncology 34 (S25) , 448.

Baird, Richard, Banks, Ian, Cameron, David, Chester, John D., Earl, Helena, Flannagan, Mark, Januszewski, Adam, Kennedy, Richard, Payne, Sarah, Samuel, Emlyn, Taylor, Hannah, Agarwal, Roshan, Ahmed, Samreen, Archer, Caroline, Board, Ruth, Carser, Judith, Copson, Ellen, Cunningham, David, Coleman, Rob, Dangoor, Adam, Dark, Graham, Eccles, Diana, Gallagher, Chris, Glaser, Adam, Hall, Geoff, Hall, Marcia, Harari, Danielle, Hawkins, Michael, Hill, Mark, Johnson, Peter, Jones, Alison, Kalsi, Tania, Karapanagiotou, Elena, Kemp, Zoe, Mansi, Janine, Marshall, Ernie, Mitchell, Alex, Moe, Maung, Michie, Caroline, Neal, Richard, Newsom-Davis, Tom, Norton, Alison, Osborne, Richard, Patel, Gargi, Radford, John, Ring, Alistair, Shaw, Emily, Skinner, Rod, Stark, Dan, Turnbull, Sam, Velikova, Galina, White, Jeff, Young, Alison, Joffe, Johnathan and Selby, Peter 2016. An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients. ecancermedicalscience 10 , 608. 10.3332/ecancer.2016.608
file

Hulin-Curtis, Sarah, Uusi-Kerttula, Hanni, Jones, Rachel, Baker, Andrew, Chester, John D. and Parker, Alan L. 2015. Evaluation of CD46 utilising adenoviral vectors for clinical ovarian cancer applications [Abstract]. Human Gene Therapy 26 (9) , A33-A34. 10.1089/hum.2015.29005.abstracts

Uusi-Kerttula, Hanni, Davies, James, Coughlan, Lynda, Jones, Rachel, Chester, John D. and Parker, Alan L. 2015. Development of an Ad5 vector pseudotyped with Ad48 knob protein and targeted to αvβ6 integrin efficiently targets tumour cells and evades pre-existing immunity in clinical ascites. Human Gene Therapy 26 (9) , A33-A33. 10.1089/hum.2015.29005.abstracts

Uusi-Kerttula, Hanni, Legut, Mateusz, Davies, James, Jones, Rachel, Hudson, Emma, Hanna, Louise, Stanton, Richard J., Chester, John D. and Parker, Alan L. 2015. Modulation of Ad5 fibre knob as a means of circumventing pre-existing immunity in clinical ovarian ascites. Human Gene Therapy 26 (9) , A23-A23. 10.1089/hum.2015.29005.abstracts

Jackson, Sarah E. and Chester, John D. 2015. Personalised cancer medicine. International Journal of Cancer 137 (2) , pp. 262-266. 10.1002/ijc.28940

Crusz, Santhini and Chester, John D. 2015. Muscle invasive transitional cell carcinoma of the bladder. In: Bhattacharyya, M., Payne, S. and McNeish, I. eds. Challenging Concepts in Oncology, Oxford: Oxford University Press, pp. 133-142.

Uusi-Kerttula, Hanni, Legut, Mateusz, Davies, James Anthony, Jones, Rachel, Hudson, Emma, Hanna, Louise, Stanton, Richard James, Chester, John D. and Parker, Alan L. 2015. Incorporation of peptides targeting EGFR and FGFR1 into the adenoviral fibre knob domain, and their evaluation as targeted cancer therapies. Human Gene Therapy 26 (5) , pp. 320-329. 10.1089/hum.2015.015
file

Geldart, Thomas, Chester, John D., Casbard, Angela C., Crabb, Simon, Elliott, Tony, Protheroe, Andrew, Huddart, Robert A., Mead, Graham, Barber, Jim, Jones, Robert J., Smith, Joanna D., Cowles, Robert, Evans, Jessica and Griffiths, Gareth 2015. SUCCINCT: An open-label, single-arm, non-randomised, Phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma. European Urology 67 (4) , pp. 599-602. 10.1016/j.eururo.2014.11.003
file

Sternberg, Cora N., Skoneczna, Iwona, Kerst, J Martijn, Albers, Peter, Fossa, Sophie D., Agerbaek, Mads, Dumez, Herlinde, de Santis, Maria, Théodore, Christine, Leahy, Michael G, Chester, John D., Verbaeys, Antony, Daugaard, Gedske, Wood, Lori, Witjes, J Alfred, de Wit, Ronald, Geoffrois, Lionel, Sengelov, Lisa, Thalmann, George, Charpentier, Danielle, Rolland, Frédéric, Mignot, Laurent, Sundar, Santhanam, Symonds, Paul, Graham, John, Joly, Florence, Marreaud, Sandrine, Collette, Laurence and Sylvester, Richard 2015. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3?pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. The Lancet Oncology 16 (1) , pp. 76-86. 10.1016/S1470-2045(14)71160-X

Collins, Jemima, Noble, Simon Ian Robert, Chester, John D., Davies, Helen E., Evans, William D., Lester, Jason, Parry, Diane, Pettit, Rebecca J. and Byrne, Anthony 2015. Association of sarcopenia and observed physical performance with attainment of multidisciplinary team planned treatment in non-small cell lung cancer: an observational study protocol. BMC Cancer 15 , pp. 401-413. 10.1186/s12885-015-1565-6
file

Chester, John D. and Brown, S. R. 2014. Chemo-radio-sensitisation in head and neck cancer. In: Brown, S. R., Gregory, W. M., Twelves, C. J. and Brown, J. M. eds. A Practical Guide to Designing Phase II Trials in Oncology, Statistics in Practice, Wiley, pp. 151-159.

Collins, Jemima, Noble, Simon Ian Robert, Chester, John D., Coles, Bernadette Mary and Byrne, Anthony 2014. The assessment and impact of sarcopenia in lung cancer: a systematic literature review. BMJ Open 4 (1) , e003697. 10.1136/bmjopen-2013-003697
file

Nicholson, S., Hall, E., Harland, S., Chester, John D, Pickering, L., Barber, J., Elliott, T., Thomson, A., Burnett, S., Cruickshank, C., Carrington, B., Waters, R. and Bahl, A. 2013. Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001). British Journal of Cancer 109 (10) , pp. 2554-2559. 10.1038/bjc.2013.620

Jones, Robert, Vuky, Jacqueline, Elliott, Tony, Mead, Graham, Arranz, Jose Angel, Chester, John D., Chowdhury, Simon, Dudek, Arkadiusz Z., Muller-Mattheis, Volker, Grimm, Marc-Oliver, Gschwend, Jurgen E., Wulfing, Christian, Albers, Peter, Li, Jianguo, Osmukhina, Anna, Skolnik, Jeffrey and Hudes, Gary 2013. Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. Investigational New Drugs 31 (4) , pp. 1001-1007. 10.1007/s10637-013-9926-y

Blick, Christopher, Hall, Peter, Pwint, Thinn, Al-Terkait, Falsall, Crew, Jeremy, Powles, Thomas, Macaulay, Valentine, Munro, Nicholas, Douglas, David, Kilbey, Nevlana, Protheroe, Andrew and Chester, John D. 2012. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder. Cancer 118 (16) , pp. 3920-3927. 0.1002/cncr.26675

Blick, Christopher, Hall, Peter, Pwint, Thinn, Al-Terkait, Faisal, Crew, Jeremy, Powles, Thomas, Macaulay, Valentine, Munro, Nicholas, Douglas, David, Kilbey, Neviana, Protheroe, Andrew and Chester, John D. 2012. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder. Cancer 118 (16) , pp. 3920-3927. 10.1002/cncr.26675

Karapanagiotou, Eleni M., Roulstone, Victoria, Twigger, Katie, Ball, Mercel, Tanay, MaryAnne, Nutting, Chris, Newbold, Kate, Gore, Martin E., Larkin, James, Syrigos, Konstantinos N., Coffey, Matt, Thompson, Brad, Mettinger, Karl, Vile, Richard G., Pandha, Hardev S., Hall, Geoff D., Melcher, Alan A., Chester, John D. and Harrington, Kevin J. 2012. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clinical Cancer Research 18 (7) , p. 2080. 10.1158/1078-0432.CCR-11-2181

Conway, Caroline, Chalkley, Rebecca, High, Alec, Maclennan, Kenneth, Berri, Stefano, Chengot, Preetha, Alsop, Melissa, Egan, Philip, Morgan, Joanne, Taylor, Graham R., Chester, John D., Sen, Mehmet, Rabbitts, Pamela and Wood, Henry M. 2012. Next-generation sequencing for simultaneous determination of human papillomavirus load, subtype, and associated genomic copy number changes in tumors. The Journal of Molecular Diagnostics 14 (2) , pp. 104-111. 10.1016/j.jmoldx.2011.10.003

Karanpanagiotou, Eleni M., Roulstone, Victoria, Twigger, Katie, Ball, Mercel, Tanay, MaryAnne, Nutting, Chris, Newbold, Kate, Gore, Martin E., Larkin, James, Syrigos, Konstantinos N., Coffey, Matt, Thompson, Brad, Mettinger, Karl, Vile, Richard G., Pandha, Hardev s., Hall, Geoff D., Melcher, Alan A., Chester, John D. and Harrington, Kevin J. 2012. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clinical Cancer Research 18 (7) , pp. 2080-2089. 10.1158/1078-0432.CCR-11-2181

Harvey, T. J., Hennig, I. M., Shnyder, S. D., Cooper, P. A., Ingram, N., Hall, G. D., Selby, P. J. and Chester, John D. 2011. Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo. Cancer Gene Therapy 18 (11) , pp. 773-784. 10.1038/cgt.2011.43

Naik, Jay D., Twelves, Christopher J., Selby, Peter J., Vile, Richard G. and Chester, John D. 2011. Immune recruitment and therapeutic synergy: Keys to optimizing oncolytic viral therapy? Clinical Cancer Research 17 (13) , pp. 4214-4224. 10.1158/1078-0432.CCR-10-2848

Kottke, Timothy, Errington, Fiona, Pulido, Jose, Galivo, Feorillo, Thompson, Jill, Wongthida, Phonphimon, Diaz, Rosa Maria, Chong, Heung, Ilett, Elizabeth, Chester, John D., Pandha, Hardev, Harrington, Kevin, Selby, Peter, Melcher, Alan and Vile, Richard 2011. Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nature Medicine 17 (7) , pp. 854-859. 10.1038/nm.2390

Lamont, F. R., Tomlinson, D. C., Cooper, P. A., Shnyder, S. D., Chester, John D. and Knowles, M. A. 2011. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. British Journal of Cancer 104 (1) , pp. 75-82. 10.1038/sj.bjc.6606016

Kottke, Timothy, Errington, Fiona, Pulido, Jose, Galivo, Feorillo, Thompson, Jill, Wongthida, P., Diaz, Rosa Maria, Chong, Heung, llett, Elizabeth, Chester, John D., Pandha, Hardev, Harrington, Kevin, Selby, Peter, Melcher, Alan and Vile, Richard 2011. Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nature Medicine 17 (7) , pp. 854-859. 10.1038/nm.2390.

Kottke, Timothy, Chester, John D., Ilett, Elizabeth, Thompson, Jill, Diaz, Rosa Maria, Coffey, Matt, Selby, Peter, Nuovo, Gerard, Pulida, Jose, Mukhopadhyay, Debabrata, Pandha, Hardev, Harrington, Kevin, Melcher, Alan and Vile, Richard 2011. Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy. Molecular Therapy 19 (10) , pp. 1802-1812. 10.1038/mt.2011.147

Rimmer, Y., Chester, John D., Joffe, J., Stark, D., Shamash, J., Powles, T., White, J., Wason, J., Parashar, D., Mazhar, D. and Williams, M.V. 2011. Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour. British Journal of Cancer 105 (6) , pp. 766-772. 10.1038/bjc.2011.309

Harvey, T. J., Burdon, D., Steele, L., Ingram, N., Hall, G. D., Selby, P. J., Vile, R. G., Cooper, P. A., Shnyder, S. D. and Chester, John D. 2010. Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor. Gene Therapy 17 (8) , pp. 1000-1010. 10.1038/gt.2010.45

Kottke, Timothy, Hall, Geoff, Pulido, Jose, Diaz, Rosa Maria, Thompson, Jill, Chong, Heung, Selby, Peter, Coffey, Matt, Pandha, Hardev, Chester, John D., Melcher, Alan, Harrington, Kevin and Vile, Richard 2010. Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. The Journal of Clinical Investigation 120 (5) , pp. 1551-1560. 10.1172/JCI41431
file

Harrington, K. J., Vile, R. G., Melcher, A., Chester, John D. and Pandha, H. 2010. Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine & Growth Factor Reviews 21 (2-3) , pp. 91-98.

Young, Alison, Madi, Ayman, Treanor, Darren, Millson, Charles, Selby, Peter and Chester, John D. 2010. Fulminant hepatic failure in a patient with advanced extragonadal germ cell tumour. BMJ Case Reports 2010 10.1136/bcr.01.2010.2661

Patel, P., Young, J. G., Mautner, V., Ashdown, D., Bonney, S., Pineda, R. G., Collins, S. I., Searle, P. F., Hull, D., Peers, E., Chester, John D., Wallace, D. M., Doherty, A., Leung, H., Young, L. S. and James, N. D. 2009. Corrigendum to "A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase With CB1984" (vol 17, pg 1292, 2009) [Corrigendum]. Molecular Therapy 17 (7) , p. 1302. 10.1038/mt.2009.110

Patel, P., Young, J. G., Mautner, V., Ashdown, D., Bonney, S., Pineda, R. G., Collins, S. I., Searle, P. F., Hull, D., Peers, E., Chester, John D., Wallace, D. M., Doherty, A., Leung, H., Young, L. S. and James, N. D. 2009. A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase with CB1954. Molecular Therapy 17 (7) , pp. 1292-1299. 10.1038/mt.2009.80

Kottke, T., Diaz, R. M., Kaluza, K., Pulido, J., Galivo, F., Wongthida, P., Thompson, J., Willmon, C., Barber, G. N., Chester, John D., Selby, P., Strome, S., Harrington, K., Melcher, A. and Vile, R. G. 2008. Use of biological therapy to enhance both virotherapy and adoptive t-cell therapy for cancer. Molecular Therapy 16 (12) , pp. 1910-1918. 10.1038/mt.2008.212

Karapanagiotou, E., Pandha, H., Hall, G., Chester, John D., Melcher, A., De Bono, J., Gore, M., Nutting, C. and Harrington, K. 2008. Phase I Trial of Oncolytic Reovirus (Reolysin) in Combination With Carboplatin/Paclitaxel in Patients With Advanced Solid Cancers [Abstract]. Journal of Immunotherapy 31 (9) , p. 952. 10.1097/CJI.0b013e31818b1dce

Kottke, T., Galivo, F., Wongthida, P., Diaz, R. M., Thompson, J., Jevremovic, D., Barber, G. N., Hall, G., Chester, John D., Selby, P., Harrington, K., Melcher, A. and Vile, R. G. 2008. Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Molecular Therapy 16 (7) , pp. 1217-1226. 10.1038/mt.2008.83

Qiao, J., Wang, H., Kottke, T., Diaz, R., Willmon, C., Hudacek, A., Thompson, J., Parato, K., Bell, J., Naik, J., Chester, John D., Selby, P., Harrington, K., Melcher, A. and Vile, R. G. 2008. Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Therapy 15 (8) , pp. 604-616. 10.1038/sj.gt.3303098

Seymour, M. T., Trigonis, I., Finan, P. J., Halstead, F., Dunham, R., Wilson, G., Farrugia, D., Chester, John D., King, J., Brown, C. B., Slevin, M. L. and Joel, S. P. 2008. A feasibility, pharmacokinetic and frequency-escalation trial of intraperitoneal chemotherapy in high risk gastrointestinal tract cancer. European Journal of Surgical Oncology (EJSO) 34 (4) , pp. 403-409. 10.1016/j.ejso.2007.05.007

Qiao, Jian, Kottke, Timothy, Willmon, Candice, Galivo, Feorillo, Wongthida, Phonphimon, Diaz, Rosa Maria, Thompson, Jill, Ryno, Pamela, Barber, Glen N., Chester, John D., Selby, Peter, Harrington, Kevin, Melcher, Alan and Vile, Richard G. 2008. Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nature Medicine 14 (1) , pp. 37-44. 10.1038/nm1681

Theodore, C., Skoneczna, I., Bodrogi, I., Leahy, M., Chester, John D., Kerst, J. M., Collette, L., Ven, K., Marreaud, S. and Oliver, R. T. D. 2007. 4502 ORAL Phase 2 study of irinotecan and cisplatin in epidermoid carcinoma of the penis (EORTC 30992) [Abstract]. EJC Supplements 5 (4) , p. 299. 10.1016/S1359-6349(07)71133-3

Thanarajasingam, Uma, Sanz, Laura, Diaz, Rosa, Qiao, Jian, Sanchez-Perez, Luis, Kottke, Timothy, Thompson, Jill, Chester, John D. and Vile, Richard G. 2007. Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy. Cancer Research 67 (1) , pp. 300-308. 10.1158/0008-5472.CAN-06-1017

Chester, John D., Ruchatz, A., Gough, M., Crittenden, M., Chong, H., Loic-Cosset, F., Diaz, R. M., Harrington, K., Alvarez-Vallina, L. and Vile, R. 2006. Corrigendum: Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells (vol 20, pg 256, 2002) [Corrigendum]. Nature Biotechnology 24 (10) , p. 1293. 10.1038/nbt1006-1293b

El-Helw, L. M., Naik, J. D., Chester, John D., Joffe, J. K., Selby, P. J. and Coleman, R. E. 2006. High-dose chemotherapy with haematopoietic stem-cell support in patients with poor prognosis, relapsed or refractory germ cell tumours. BJU International 98 (3) , pp. 519-525. 10.1111/j.1464-410X.2006.06389.x

Hall, G. D., Smith, B., Weeks, R. J., Selby, P. J., Southgate, J. and Chester, John D. 2006. Novel urothelium specific gene expression identified by differential display reverse transcriptase-polymerase chain reaction. The Journal of Urology 175 (1) , pp. 337-342. 10.1016/S0022-5347(05)00006-6

Cole, C., Qiao, J., Kottke, T., Diaz, R. M., Ahmed, A., Sanchez-Perez, L., Brunn, G., Thompson, J., Chester, John D. and Vile, R. G. 2005. Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nature Medicine 11 (10) , pp. 1073-1081. 10.1038/nm1297

Hall, G. D., Weeks, R. J., Olsburgh, J., Southgate, J., Knowles, M. A., Selby, P. J. and Chester, John D. 2005. Transcriptional control of the human urothelial-specific gene, uroplakin Ia. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression 1729 (2) , pp. 126-134. 10.1016/j.bbaexp.2005.04.004

Chester, John D., Hall, G. D., Forster, M. and Protheroe, A. S. 2004. Systemic chemotherapy for patients with bladder cancer - current controversies and future directions. Cancer Treatment Reviews 30 (4) , pp. 343-358. 10.1016/j.ctrv.2003.12.005

Hennig, I. M., Harvey, T. J., Vile, R. G., Selby, P. S. and Chester, John D. 2004. Hypoxia-selective expression of systemically-delivered macrophage-based cancer gene therapy vectors for treatment of disseminated malignancy [Abstract]. Annals of Oncology 15 (S3) , p. 25.

Crittenden, M., Gough, M., Chester, John D., Kottke, T., Thompson, J., Ruchatz, A., Clackson, T., Cosset, F. L., Chong, H., Diaz, R. M., Harrington, K., Alvarez-Vallina, L. and Vile, R. 2003. Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy. Cancer Research 63 (12) , pp. 3173-3180.

Hennig, I., Jevremovic, D., Gulati, R., Gough, M., Crittenden, M., Cosset, F. L., Alvarez-Vallina, L., Clackson, T., Chester, John D., Simari, R. and Vile, R. 2003. Human endothelial precursor cells as carriers for therapeutic gene delivery to tumors [Abstract]. Molecular Therapy 7 (5) , S129. 10.1006/mthe.2003.0983

Chester, John D., Joel, S. P., Cheeseman, S. L., Hall, G. D., Braun, M. S., Perry, J., Davis, T., Button, C. J. and Seymour, M. T. 2003. Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fluorouracil-refractory metastatic colon cancer. Journal of Clinical Oncology 21 (6) , pp. 1125-1132. 10.1200/JCO.2003.08.049

Chester, John D., Kennedy, W., Hall, G. D., Selby, P. J. and Knowles, M. A. 2003. Adenovirus-mediated gene therapy for bladder cancer: efficient gene delivery to normal and malignant human urothelial cells in vitro and ex vivo. Gene Therapy 10 (2) , pp. 172-179. 10.1038/sj.gt.3301851

Cheeseman, S. L., Joel, S. P., Chester, John D., Wilson, G., Dent, J. T., Richards, F. J. and Seymour, M. T. 2002. A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. British Journal of Cancer 87 (4) , pp. 393-399. 10.1038/sj.bjc.6600467

Chester, John D., Ruchatz, A., Gough, M., Crittenden, M., Chong, H., Loic-Cosset, L., Diaz, R. M., Harrington, K., Alvarez-Vallina, L. and Vile, R. 2002. Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells. Nature Biotechnology 20 (3) , pp. 256-263. 10.1038/nbt0302-256

Gough, M., Ruchatz, A., Chester, John D., Chong, H., Cosset, F. L., Diaz, R. M., Alvarez-Vallina, L. and Vile, R. 2002. Using T cells to deliver transgenes to target cells: antigen specific virus production and tissue-specific transgene expression for targeted delivery [Abstract]. FASEB Journal 16 (4) , A335-A336.

Emiliusen, L., Gough, M., Bateman, A., Ahmed, A., Voellmy, R., Chester, John D., Diaz, R. M., Harrington, K. and Vile, R. 2001. A transcriptional feedback loop for tissue-specific expression of highly cytotoxic genes which incorporates an immunostimulatory component. Gene Therapy 8 (13) , pp. 987-998.

Chester, John D., Diaz, R. M., Ruchatz, A., Chong, H., Clackson, T., Cosset, F. L., Alvarez-Vallina, L., Russell, S. J., Harrington, K. J. and Vile, R. G. 2001. Cell-based vector delivery for cancer gene therapy [Abstract]. British Journal of Cancer 85 (S1) , p. 24. 10.1054/bjoc.2001.1917

Chester, John D., Howarth, M., Clark, C. J. P., Goldesbrough, D. R., Bogle, S. E., Bradley, C. J. and Parker, D. 2001. Management of lymphoma patients in a Cancer Unit: An audit of 15 years' experience in a District General Hospital [Abstract]. British Journal of Cancer 85 (S1) , p. 72. 10.1054/bjoc.2001.1918

Chester, John D., Clark, C. J. P., Gouldesbrough, D. R., Bogle, S. M., Bradley, C. J. and Parker, D. 2001. Management of lymphoma patients in a cancer unit: An audit of 15 years' experience in a district general hospital. Clinical Oncology 13 (4) , pp. 243-250. 10.1053/clon.2001.9263

Chester, John D., Button, C. J., Fallon, S., Cheeseman, S. L., Farrugia, D., Perry, J., Joel, S. P. and Seymour, M. T. 2000. A phase I and pharmacokinetic trial of intravenous irinotecan plus oral cyclosporin in 5-FU refractory metastatic colon cancer [Abstract]. Clinical Cancer Research 6 (S) , p. 4515.

Chester, John D., Dent, J. T., Wilson, G., Ride, E. and Seymour, M. T. 2000. Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer. Annals of Oncology 11 (2) , pp. 235-237.

Chester, John D., Dent, J. T., Wilson, G., Ride, E. and Seymour, M. T. 1999. Protracted infusional 5FU+mitomycin in 5FU-resistant colorectal cancer [Abstract]. British Journal of Cancer 80 (S) , p. 55.

Wyld, D. K., Chester, John D. and Perren, T. J. 1998. Endocrine aspects of the clinical management of breast cancer - current issues. Endocrine-Related Cancer 5 (2) , pp. 97-110. 10.1677/erc.0.0050097

Thiele, B. J., Chester, John D., Oprey, J., Hohne, W. E. and Harrison, P. R. 1991. Structure and regulation of the gene encoding the erythroid-spcecific rabbit 15-lipoxygenase [Abstract]. Biological Chemistry 372 (2) , p. 789. 10.1515/bchm3.1991.372.2.785

Thiele, B. J., Fleming, J., Chester, John D., Oprey, J., Prehn, S., Janetzki, S., Rapoport, S. M. and Harrison, P. R. 1990. Structure of the Messenger-RNA and of the gene coding for the Rabbit Erythroid 15-Lipoxygenase. Biomedica Biochimica Acta 49 (2-3) , S17-S24.

Harrison, P. R., Plumb, M., Frampton, J., Thiele, B., MacLeod, K., Chester, John D., Chambers, I., Fleming, J., Oprey, J., Walker, M., Wainwright, H., Lowe, S. and Janetzki, S. 1990. Regulation of erythroid-specific gene-expression. Biomedica Biochimica Acta 49 (2-3) , S5-S10.

Oprey, J., Chester, John D., Thiele, B. J., Janetzki, S., Prehn, S., Fleming, J. and Harrison, P. R. 1989. The promoter structure and complete sequence of the gene encoding the rabbit erythroid cell-specific 15-lipoxygenase. Gene 84 (2) , pp. 493-499. 10.1016/0378-1119(89)90526-X

Fleming, J., Thiele, B. J., Chester, John D., Oprey, J., Janetzki, S., Aitken, A., Anton, I. A., Rapoport, S. M. and Harrison, P. R. 1989. The complete sequence of the rabbit erythroid cell-specific 15-lipoxygenase mRNA: comparison of the predicted amino acid sequence of the erythrocyte lipoxygenase with other lipoxygenases. Gene 79 (1) , pp. 181-188. 10.1016/0378-1119(89)90103-0

Harrison, P. R., Plumb, M., Frampton, J., Llewellyn, D., Chester, John D., Chambers, I., MacLeod, K., Fleming, J., Oprey, J., Walker, M., Wainwright, H. and Anton, I. 1988. Regulation of erythroid cell-specific gene expression during erythropoiesis. British Journal of Cancer Supplement 58 (S) , pp. 46-51.

Harrison, P. R., Plumb, M., Frampton, J., Chambers, I., Llewellyn, D., Chester, John D., MacLeod, K., Fleming, J., Oprey, J., Walker, M. and Wainwright, H. 1988. cis and trans control of erythroid cell-specific gene expression during erythropoiesis. Journal of Cell Science (S10) , pp. 145-155.

Thiele, B. J., Fleming, J., Kasturi, K., Oprey, J., Black, E., Chester, John D., Rapoport, S. M. and Harrison, P. R. 1987. Cloning of a rabbit erythroid-cell-specific lipoxygenase mRNA. Gene 57 (1) , pp. 111-119. 10.1016/0378-1119(87)90182-X

Fulton, A. M., Mellor, J., Dobson, M. J., Chester, John D., Warmington, J. R., Indge, K. J., Oliver, S. G., de la Paz, P., Wilson, W., Kingsman, A. J. and Kingsman, S. M. 1985. Variants within the yeast Ty sequence family encode a class of structurally conserved proteins. Nucleic Acids Research 13 (11) , pp. 4097-4112. 10.1093/nar/13.11.4097

This list was generated on Sat Sep 21 05:10:37 2019 BST.